Cargando…

Moving beyond disclosure: Stages of care in preclinical Alzheimer's disease biomarker testing

Alzheimer's disease (AD) begins with an asymptomatic “preclinical” phase, in which abnormal biomarkers indicate risk for developing cognitive impairment. Biomarker information is increasingly being disclosed in research settings, and is moving toward clinical settings with the development of ch...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ketchum, Fred B., Chin, Nathaniel A., Grill, Joshua, Gleason, Carey E., Erickson, Claire, Clark, Lindsay R., Paulsen, Jane S., Kind, Amy J.H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Perspectives
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9402800/ https://www.ncbi.nlm.nih.gov/pubmed/35213786 http://dx.doi.org/10.1002/alz.12620

Ejemplares similares

Implications of preclinical Alzheimer's disease biomarker disclosure for US policy and society
por: Erickson, Claire M., et al.
Publicado: (2022)

Research Participant Interest in Alzheimer’s Disease Biomarker Disclosure
por: Erickson, Claire, et al.
Publicado: (2020)

Disclosure of preclinical Alzheimer's disease biomarker results in research and clinical settings: Why, how, and what we still need to know
por: Erickson, Claire M., et al.
Publicado: (2021)

What Influences the Willingness of Blacks and African Americans to Enroll in Preclinical Alzheimer’s Disease Biomarker Research? A Qualitative Vignette Analysis
por: Ketchum, Fred B., et al.
Publicado: (2022)

Predictors of positive or negative reactions to learning Alzheimer’s biomarker results
por: Erickson, Claire, et al.
Publicado: (2021)

Virtual disclosure of preclinical Alzheimer's biomarkers: Preliminary experiences
por: Erickson, Claire M., et al.
Publicado: (2021)

The importance of the dyad: Participant perspectives on sharing biomarker results in Alzheimer's disease research
por: Ketchum, Fred B., et al.
Publicado: (2023)

Anticipated reactions to learning Alzheimer’s disease biomarker results
por: Clark, Lindsay R., et al.
Publicado: (2022)

Predictors of Willingness to Enroll in Hypothetical Alzheimer Disease Biomarker Studies that Disclose Personal Results
por: Erickson, Claire M., et al.
Publicado: (2022)

Recruiting to preclinical Alzheimer's disease clinical trials through registries
por: Grill, Joshua D.
Publicado: (2017)

Feasibility of virtual Alzheimer's biomarker disclosure: Findings from an observational cohort
por: Erickson, Claire M., et al.
Publicado: (2023)

Moving beyond the GM Debate
por: Leyser, Ottoline
Publicado: (2014)

Moving Beyond Directly Observed Therapy for Tuberculosis
por: Metcalfe, John Z., et al.
Publicado: (2015)

Cardiology clinic patient attitudes toward and potential personal utility of genetic testing: Findings from a unique multiracial clinical sample
por: Erickson, Claire M., et al.
Publicado: (2022)

The neuroscience of early intervention: Moving beyond our appeals to fear
por: Palaniyappan, Lena
Publicado: (2021)

Benchmarks for ethically credible partnerships between industry and academic health centers: beyond disclosure of financial conflicts of interest
por: Meslin, Eric M., et al.
Publicado: (2015)

Measuring cognition and function in the preclinical stage of Alzheimer's disease
por: Weintraub, Sandra, et al.
Publicado: (2018)

Moving beyond Bermuda: sharing data to build a medical information commons
por: Cook-Deegan, Robert, et al.
Publicado: (2017)

First Do No Harm: Moving Beyond Universal Preprocedural Testing for COVID-19
por: Penney, Jessica, et al.
Publicado: (2021)

Disclosure of medical errors to patients in China
por: Gao, Lei, et al.
Publicado: (2015)

Dementia in the oldest old: Beyond Alzheimer disease
por: Pierce, Aimee L., et al.
Publicado: (2017)

Biological sex differences in Alzheimer's preclinical research: A call to action
por: Waters, Ansley, et al.
Publicado: (2021)

Genealogy, Virality, and Potentiality: Moving Beyond Orientalism with COVID-19
por: Kirksey, Eben
Publicado: (2021)

Site-directed A → I RNA editing as a therapeutic tool: moving beyond genetic mutations
por: Diaz Quiroz, Juan F., et al.
Publicado: (2023)

Moving Canadian governmental policies beyond a focus on individual lifestyle: some insights from complexity and critical theories
por: Alvaro, C., et al.
Publicado: (2011)

Key Elements of Effective and Practical Disclosure Policies for Health Science Journals
por: Sass, Jennifer
Publicado: (2009)

Cognitive reserve and lifestyle: moving towards preclinical Alzheimer’s disease
por: Arenaza-Urquijo, Eider M., et al.
Publicado: (2015)

Treatable traits in asthma: moving beyond diagnostic labels
por: McDonald, Vanessa M, et al.
Publicado: (2022)

Disclosure of individual research results at federally funded Alzheimer's Disease Research Centers
por: Roberts, J. Scott, et al.
Publicado: (2021)

Can I be sued for that? Liability risk and the disclosure of clinically significant genetic research findings
por: McGuire, Amy L., et al.
Publicado: (2014)

How would preclinical Alzheimer’s disease (AD pathology) occur? An insight from a genomic instability mouse model
por: Rao, Chinthalapally V., et al.
Publicado: (2021)

GluN2B-NMDA receptors in Alzheimer's disease: beyond synapse loss and cell death
por: Zhou, Qiang
Publicado: (2014)

Informed consent disclosure to vaccine trial subjects of risk of COVID‐19 vaccines worsening clinical disease
por: Cardozo, Timothy, et al.
Publicado: (2020)

When genes move, genomes collide
por: Brandvain, Yaniv, et al.
Publicado: (2018)

Alzheimer's disease biomarkers in Black and non‐Hispanic White cohorts: A contextualized review of the evidence
por: Gleason, Carey E., et al.
Publicado: (2021)

Going beyond established model systems of Alzheimer’s disease: companion animals provide novel insights into the neurobiology of aging
por: de Sousa, Alexandra A., et al.
Publicado: (2023)

Preterm birth prevention—Time to PROGRESS beyond progesterone
por: Norman, Jane E., et al.
Publicado: (2017)

The Economics of Reproducibility in Preclinical Research
por: Freedman, Leonard P., et al.
Publicado: (2015)

Study partners should be required in preclinical Alzheimer’s disease trials
por: Grill, Joshua D., et al.
Publicado: (2017)

Safety Testing: Moving Toward Alternative Methods
por: Birnbaum, Linda S, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_jq6v01hl5i3kdnph1mq3rbpiol